Search clinical trials for: PF-07321332/ritonavir Dabigatran

Total 27 results

Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Healthy Participants

United States
Pfizer

Completed

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

Bioavailability

United States
Pfizer

Completed

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

Renal Impairment

United States
Pfizer

Completed

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

COVID-19

United States, Russian Federation, Thailand, Czechia, Colombia, Bulgaria, Japan, South Africa, Turkey, Argentina, Hungary, Malaysia, Mexico, Poland, Spain, Ukraine, Brazil
Pfizer

Withdrawn

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Healthy Participants
Pfizer

Completed

A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women

Healthy Participants

Belgium
SpringWorks Therapeutics, Inc.

Active, not recruiting

Nirogacestat in Ovarian Granulosa Cell Tumors

Ovarian Cancer | Ovarian Granulosa Cell Tumor | Ovarian Granulosa-Stromal Tumor

United States, Canada, Poland
Pfizer

Completed

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

Bioavailability

United States
Pfizer

Completed

A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.

Healthy Participants

China
Pfizer

Terminated

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

COVID-19

United States
Pfizer

Completed

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Healthy Participants

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

COVID-19

United States
Pfizer

Completed

Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir

Healthy Participant

United States
Pfizer

Completed

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

COVID-19

United States, Korea, Republic of, Russian Federation, Czechia, Turkey, Malaysia, South Africa, Bulgaria, Poland, Hungary, Argentina, Brazil, Colombia, Japan, Mexico, Puerto Rico, Spain, Thailand, Ukraine, India
Pfizer

Completed

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Hepatic Impairment

United States
Pfizer

Terminated

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

COVID-19

United States, Malaysia, Thailand, Turkey, Spain, Czechia, Poland, Bulgaria, Japan, Korea, Republic of, South Africa, Hungary, Argentina, Brazil, Colombia, Mexico, Puerto Rico, Romania, Slovakia, Ukraine
Pfizer
Arvinas Estrogen Receptor, Inc.

Completed

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Healthy

Belgium
Pfizer

Completed

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

Healthy Participant

Belgium
Pfizer

Completed

Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants

Healthy Participants

Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditions

United States
Pfizer

Terminated

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Healthy

Belgium
Pfizer

Completed

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Healthy

Belgium
Italfarmaco

Completed

Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity

Drug-Drug Interaction

Portugal
Lagos State Health Service Commission

Unknown

Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering

Post Anaesthetic Shivering
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States

3

Subscribe